A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.

What Was Tested

This randomized controlled trial looks at Angiotensin II Type 1 Receptor Blockers in the context of hyperparathyroidism.

The AACHEN trial was a double-blind, randomized, placebo-controlled clinical multicenter trial to evaluate the effects of candesartan cilexetil on intimal hyperplasia after coronary stent implantation.

Why It Was Studied

Preliminary clinical data, however, revealed conflicting results.

Who Took Part

The abstract describes 120 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A follow-up angiography including intravascular ultrasound assessment of the target lesion was performed 24 +/- 2 weeks after stent implantation.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Angiotensin II Type 1 Receptor Blockers study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II Type 1 Receptor Blockers study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Angiotensin II Type 1 Receptor Blockers group a baseline to be compared against.

Running at several centres spread the Angiotensin II Type 1 Receptor Blockers study over different clinics and patient groups.

The primary end point was defined as the difference in neointimal area between groups as assessed by intravascular ultrasound.

Secondary end points included differences in angiographic parameters (ie, restenosis rate) and incidence of major cardiac events.

What Was Measured

PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Biphenyl Compounds, Coronary Angiography, Coronary Disease, Coronary Restenosis and Coronary Vessels.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II Type 1 Receptor Blockers in 120 patients in people with hyperparathyroidism.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (American heart journal), a journal based in United States.

More context: Hyperparathyroidism research.